14.34
Schlusskurs vom Vortag:
$14.47
Offen:
$14.35
24-Stunden-Volumen:
420.03K
Relative Volume:
0.29
Marktkapitalisierung:
$2.08B
Einnahmen:
$340.81M
Nettoeinkommen (Verlust:
$-419.65M
KGV:
-5.0316
EPS:
-2.85
Netto-Cashflow:
$-402.10M
1W Leistung:
-1.22%
1M Leistung:
-0.33%
6M Leistung:
-35.41%
1J Leistung:
-39.21%
Denali Therapeutics Inc Stock (DNLI) Company Profile
Firmenname
Denali Therapeutics Inc
Sektor
Branche
Telefon
(650) 866-8547
Adresse
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Vergleichen Sie DNLI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
DNLI
Denali Therapeutics Inc
|
14.34 | 2.01B | 340.81M | -419.65M | -402.10M | -2.85 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
588.61 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.06 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2025-03-07 | Fortgesetzt | Morgan Stanley | Overweight |
2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
2025-01-07 | Eingeleitet | Robert W. Baird | Outperform |
2025-01-03 | Eingeleitet | William Blair | Outperform |
2024-12-16 | Hochstufung | Stifel | Hold → Buy |
2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
2024-10-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-12-13 | Eingeleitet | Citigroup | Buy |
2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2023-09-06 | Eingeleitet | B. Riley Securities | Buy |
2023-01-30 | Eingeleitet | SVB Securities | Outperform |
2022-12-05 | Eingeleitet | Cowen | Outperform |
2022-11-02 | Hochstufung | BTIG Research | Neutral → Buy |
2022-11-02 | Eingeleitet | BofA Securities | Buy |
2022-06-23 | Eingeleitet | Berenberg | Buy |
2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
2021-09-21 | Eingeleitet | Oppenheimer | Outperform |
2021-09-01 | Eingeleitet | SMBC Nikko | Outperform |
2021-05-18 | Eingeleitet | UBS | Buy |
2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
2021-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2020-11-11 | Bestätigt | H.C. Wainwright | Buy |
2020-10-16 | Herabstufung | BTIG Research | Buy → Neutral |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-08-20 | Bestätigt | H.C. Wainwright | Buy |
2020-03-13 | Hochstufung | Evercore ISI | In-line → Outperform |
2020-02-28 | Hochstufung | Wedbush | Neutral → Outperform |
2020-02-24 | Eingeleitet | Jefferies | Buy |
2020-02-19 | Eingeleitet | Stifel | Hold |
2020-01-27 | Hochstufung | Goldman | Neutral → Buy |
2019-09-26 | Eingeleitet | Wedbush | Neutral |
2019-09-13 | Eingeleitet | Nomura | Buy |
2019-08-09 | Eingeleitet | BTIG Research | Buy |
2019-06-26 | Eingeleitet | H.C. Wainwright | Buy |
2018-11-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-11-12 | Eingeleitet | Janney | Buy |
2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
2018-01-02 | Eingeleitet | Evercore ISI | Outperform |
2018-01-02 | Eingeleitet | Goldman | Neutral |
2018-01-02 | Eingeleitet | JP Morgan | Overweight |
2018-01-02 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
What analysts say about Denali Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
What drives Denali Therapeutics Inc. stock priceFree Technical Analysis Support - Autocar Professional
Is Denali Therapeutics Inc. a good long term investmentOutperformance with explosive growth - jammulinksnews.com
Denali Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com
What makes Denali Therapeutics Inc. stock price move sharply3x Return Stock Radar - beatles.ru
BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com
Denali Therapeutics' Insider Sale: Routine Diversification or a Cause for Concern? - AInvest
DNLI SEC FilingsDenali Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA accepts priority review for Denali’s Hunter syndrome therapy By Investing.com - Investing.com South Africa
FDA accepts priority review for Denali’s Hunter syndrome therapy - Investing.com Australia
Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug - Investing.com Nigeria
Denali Therapeutics stock gains as FDA grants priority review for Hunter syndrome drug By Investing.com - Investing.com South Africa
Denali Therapeutics Announces FDA Acceptance and Priority - GlobeNewswire
Factor Thisâ„¢ Energy Understood. All Factored In. - FinancialContent
Denali Therapeutics Insiders Sell US$1.9m Of Stock, Possibly Signalling Caution - simplywall.st
Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha
(DNLI) Proactive Strategies - news.stocktradersdaily.com
Denali Therapeutics stock poised for catalyst as FDA decision nears By Investing.com - Investing.com South Africa
(DNLI) Investment Analysis - news.stocktradersdaily.com
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance
Denali Therapeutics Enters Registration Rights Agreement - TipRanks
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Q2 EPS Estimate for Denali Therapeutics Boosted by Analyst - Defense World
Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia
Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Denali Therapeutics Inc-Aktie (DNLI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Watts Ryan J. | President and CEO |
Jul 09 '25 |
Sale |
15.00 |
495,282 |
7,429,230 |
253,071 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):